Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor

被引:97
|
作者
Dowling, Mark R. [1 ]
Charlton, Steven J. [1 ]
机构
[1] Novartis Inst Biomed Res, Horsham RH12 5AB, W Sussex, England
关键词
association rate (k(on)); competition binding; dissociation rate (k(off)); duration of drug action; equilibrium; kinetics; muscarinic acetylcholine receptor; tiotropium;
D O I
10.1038/sj.bjp.0706819
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Slow receptor dissociation kinetics has been implicated in the long clinical duration of action of the muscarinic receptor antagonist tiotropium. However, despite the potential benefits of new drugs with slow dissociation kinetics, the rate parameters of new compounds are seldom measured due to technical difficulties and financial implications associated with radiolabeling multiple ligands. Here we describe the development and optimisation of a medium throughput assay which is capable of measuring the kinetic parameters of novel, unlabelled compounds. 2 Radioligand binding studies were performed with membranes derived from CHO cells recombinantly expressing the human M-3 muscarinic receptor. 3 Initial characterisation of the radioligand [H-3]-NMS yielded on and off rates of 4.1 +/- 0.2 X 10(8) M-1 min(-1) and 0.015 +/- 0.0005 min(-1), respectively. 4 The specific binding of [H-3]-NMS was measured over time in the presence and absence of several concentrations of unlabelled competitor compounds. These data were analysed using a competition kinetic model to provide on and off rates for the unlabelled competitor. Comparison of the kinetically derived Kd (k(off)/k(on)) with K-i values generated at equilibrium showed an excellent correlation (r(2) = 0.99), providing good validation of the method. 5 The on and off rates were also used in theoretical computer simulations to successfully predict the effect of incubation time on apparent IC50 values. 6 This study demonstrates that a medium-throughput competition kinetic binding assay can be used to determine accurate on and off rates of unlabelled compounds, providing the opportunity to optimise for kinetic parameters early in the drug discovery process.
引用
收藏
页码:927 / 937
页数:11
相关论文
共 50 条
  • [1] Synthesis and optimization of novel and selective muscarinic M3 receptor antagonists
    Kumar, Naresh
    Kaur, Kirandeep
    Aeron, Shelly
    Dharmarajan, Sankaranarayanan
    Silamkoti, Arun D. V.
    Mehta, Anita
    Gupta, Suman
    Chugh, Anita
    Gupta, Jang B.
    Salman, Mohammad
    Palle, Venkata P.
    Cliffe, Ian A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (18) : 5256 - 5260
  • [2] Long-acting muscarinic M3 receptor antagonists -: GlaxoSmithKline
    Norman, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (09) : 1315 - 1320
  • [3] Analogues of oxybutynin as M3 selective muscarinic receptor antagonists.
    Sarma, PKS
    Kumar, N
    Kaur, K
    Chugh, A
    Gupta, S
    Dutt, A
    Gupta, JB
    Mehta, A
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U58 - U59
  • [4] Long-acting muscarinic M3 receptor antagonists -: Theravance
    Norman, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (09) : 1321 - 1326
  • [5] Discovery of long acting inhaled muscarinic M3 receptor antagonists
    Baettig, Urs
    Collingwood, Steve
    Janus, Diana
    Devereux, Nick
    Stanley, Emily
    Cox, Brian
    McCarthy, Clive
    Charlton, Steven
    Leighton-Davis, Juliette
    Fozard, John R.
    Baur, Francois
    Farr, Dave
    Mazzoni, Lazzaro
    Patel, Viral
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 750 - 750
  • [6] SYNTHESIS OF ANTAGONISTS OF MUSCARINIC (M3) RECEPTORS
    Broadley, Kenneth J.
    Davies, Robin H.
    Escargueil, Christine
    Lee, Alan T. L.
    Penson, Peter
    Thomas, Eric J.
    COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, 2011, 76 (07) : 781 - 801
  • [7] Discovery of Novel Potent Muscarinic M3 Receptor Antagonists with Proper Plasma Stability by Structural Recombination of Marketed M3 Antagonists
    Xiang, Zuojuan
    Liu, Jun
    Sun, Hongbin
    Wen, Xiaoan
    CHEMMEDCHEM, 2017, 12 (15) : 1173 - 1182
  • [8] Unbinding Kinetics of Muscarinic M3 Receptor Antagonists Explained by Metadynamics Simulations
    Galvani, Francesca
    Pala, Daniele
    Cuzzolin, Alberto
    Scalvini, Laura
    Lodola, Alessio
    Mor, Marco
    Rizzi, Andrea
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2023, 63 (09) : 2842 - 2856
  • [9] At physiological concentrations, deoxycholic acid conjugates are M3 muscarinic receptor antagonists
    Raufman, JP
    Chen, Y
    Zimniak, P
    GASTROENTEROLOGY, 2001, 120 (05) : A357 - A358
  • [10] A review of the pharmacokinetics of M3 muscarinic receptor antagonists used for the treatment of asthma
    Matera, Maria Gabriella
    Rinaldi, Barbara
    Berardo, Carmela
    Rinaldi, Michele
    Cazzola, Mario
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (02) : 143 - 148